Associated Papers
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Johnson WT et al.
Blood Advances, 2023
37078708 (PubMed )
Supplement: BLOODA_ADV-2023-009953-mmc1.xlsx › S1D_AITL_mutations
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Nixon MJ et al.
Npj Breast Cancer, 2019
31552290 (PubMed )
Supplement: 41523_2019_126_MOESM1_ESM.xlsx › Supplementary_Dataset_1
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.
Xue Z et al.
Cell Research, 2018
29795445 (PubMed )
Supplement: 41422_2018_44_MOESM7_ESM.xlsx › ___1
Select a paper to view details